Optimalization of Nephroprotection Using Atorvastatin (Sortis)

Not Applicable

Completed

• Conditions: Chronic Kidney Disease; Proteinuria

• Registration Number: NCT00572312
• Lead Sponsor: Medical University of Gdansk

Brief Summary

The main purpose of the study is find whether the addition of statin (Atorvastatin) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.

Detailed Description

The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney diseases (CKD), and inhibition of the RAAS with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) may retard CKD progression. Dual pharmacological blockade of the RAAS with ACEI and ARB is recommended as a standard renoprotective management at least in patients with nondiabetic proteinuric CKD. However, neither ACEI nor ARB, even in high doses or in concomitant usage, abrogate the progression of CKD completely. Innovative approaches are needed to keep patients with CKD off dialysis. Additional statin (Atorvastatin) pathway may prove to be such beneficial therapeutic concept.Given these facts additional administration of statin to combination treatment with ACEI and ARB, may provide additional renal protection. To shed more light on this issue, we performed a randomised open controlled study to evaluate the influence of triple therapy with ACEI and/orARB and statin on surrogate markers of kidney injury, i.e. proteinuria, markers of tubular involvement and kidney fibrosis.

Study Timeline

• Study Start: 2005-02
• Status Verified: 2007-12
• Study First Submitted: 2007-12-12
• Study First Submitted QC: 2007-12-12
• Last Update Submitted: 2007-12-12
• Study First Posted: 2007-12-13
• Last Update Posted: 2007-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Chronic kidney disease
• Stable proteinuria above 300 mg/24 hours (no variations above 25% in the last 6 months)
• Normal or slightly impaired stable renal function defined as serum creatinine level below 1.7 mg/dl (eGFR > 45 ml/min)

Exclusion Criteria

• Nephrotic syndrome
• Steroids or other immunosuppressive treatment minimum during six months before the study
• Diabetes mellitus
• Potassium serum level > 5.1 mEq/L
• Albumin serum level < 2.0mg/dL
• Creatinine serum level >2 mg/dl
• Current diagnosis of heart failure New York Heart Association (NYHA) Class II-IV
• Clinically significant valvular heart disease or second or third degree heart block without a pacemaker
• History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic cerebral attack
• History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention
• History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years
• Pregnant or nursing women
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.
• History of alcohol abuse
• NSAID abuse (more than 2 doses per week)
• Known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors, AT-1 receptor blockers and atorvastatin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Investigate the antiproteinuric effect of adding atorvastatin to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses

Secondary Outcome Measures

Name	Time	Method
Investigate the effect of the study intervention on urine excretion of N-acetyl-β-D-glucosaminidase, alfa1-microglobulin and amino-terminal propeptide of type III procollagen.